Literature DB >> 74380

Serum alpha-fetoprotein levels in patients with acute and chronic liver disease. Relation to hepatocellular regeneration and development of primary liver cell carcinoma.

N Eleftheriou, J Heathcote, H C Thomas, S Sherlock.   

Abstract

Using a radioimmunoassay technique serum alpha-fetoprotein could be detected in healthy adults in concentrations of less than 20 microgram/l. Of patients with acute, viral hepatitis 43% exhibited a transient rise of serum alpha-fetoprotein, the peak occurring eight to nine days after the maximum recorded serum aspartate transaminase activity. Patients with hepatic damage due to paracetamol poisoning were also shown to have transiently raised levels, the peak occurring earlier than in subjects with viral hepatitis. Six subjects with fatal fulminant hepatitis were studied; the three with the more protracted illness were noted to have increased levels before death. Twenty of 163 cases of chronic liver disease also had raised serum alpha-fetoprotein concentrations. In four, primary liver cell cancer developed; in two of these the serum alpha-fetoprotein levels rose progressively, and in two it remained raised but at low levels.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 74380      PMCID: PMC476528          DOI: 10.1136/jcp.30.8.704

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  13 in total

1.  Relationship of serum alpha-fetoprotein to the severity and duration of illness in patients with viral hepatitis.

Authors:  J R Bloomer; T A Waldmann; R McIntire; G Klatskin
Journal:  Gastroenterology       Date:  1975-02       Impact factor: 22.682

2.  Successful treatment of severe paracetamol overdosage with cysteamine.

Authors:  L F Prescott; R W Newton; C P Swainson; N Wright; A R Forrest; H Matthew
Journal:  Lancet       Date:  1974-04-06       Impact factor: 79.321

3.  Alpha(1)-fetoprotein in chronic liver disease.

Authors:  H K Silver; P Gold; J Shuster; N B Javitt; S O Freedman; N D Finlayson
Journal:  N Engl J Med       Date:  1974-09-05       Impact factor: 91.245

4.  Serum alpha-feto-protein. VI. The radio-immunoassay evidence for the presence of AFP in the serum of normal people and during pregnancy.

Authors:  L R Purves; M Purves
Journal:  S Afr Med J       Date:  1972-09-09

5.  Alpha-fetoprotein in acute viral hepatitis.

Authors:  T Akeyama; T Koyama; T Kamada
Journal:  N Engl J Med       Date:  1972-11-09       Impact factor: 91.245

6.  Alpha-1 fetoglobulin in the diagnosis of human hepatoma.

Authors:  M E Alpert; J Uriel; B de Nechaud
Journal:  N Engl J Med       Date:  1968-05-02       Impact factor: 91.245

7.  Foetoglobin and primary liver cancer.

Authors:  J B Smith; D Todd
Journal:  Lancet       Date:  1968-10-12       Impact factor: 79.321

8.  Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data.

Authors:  G I Abelev
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

Review 9.  Alpha-fetoprotein in primary liver cancer and other diseases.

Authors:  M Kew
Journal:  Gut       Date:  1974-10       Impact factor: 23.059

10.  Serum alpha-fetoprotein levels in acute viral hepatitis.

Authors:  M C Kew; L R Purves; I Bersohn
Journal:  Gut       Date:  1973-12       Impact factor: 23.059

View more
  13 in total

Review 1.  Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china.

Authors:  Peipei Song; Jianjun Gao; Yoshinori Inagaki; Norihiro Kokudo; Kiyoshi Hasegawa; Yasuhiko Sugawara; Wei Tang
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

2.  Immunoelectron microscopic observation of alpha-fetoprotein synthesis in human non-malignant liver tissues using immunoperoxidase methods.

Authors:  S Kinoyama; G Yamada; H Okushin; H Mimura; T Kobayashi; T Tsuji
Journal:  Gastroenterol Jpn       Date:  1988-08

Review 3.  Utility of screening for hepatocellular carcinoma among cirrhotics.

Authors:  Polly Niravath; Teresa Hayes; Susan Hilsenbeck
Journal:  Frontline Gastroenterol       Date:  2011-03-17

4.  Reciprocal changes in serum albumin and alpha-fetoprotein levels in the recovery course of acute viral hepatitis stimulated by glucagon and insulin therapy: analysis of a double blind controlled trial.

Authors:  K Fujiwara; I Ogata; H Oka
Journal:  Gastroenterol Jpn       Date:  1989-04

5.  Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus.

Authors:  Takashi Kumada; Hidenori Toyoda; Seiki Kiriyama; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori; Toshifumi Tada; Junko Tanaka; Hiroshi Yoshizawa
Journal:  J Gastroenterol       Date:  2010-12-07       Impact factor: 7.527

6.  Alpha-fetoprotein concentrations measured by radioimmunoassay in diagnosing and excluding hepatocellular carcinoma.

Authors:  P J Johnson; B Portmann; R Williams
Journal:  Br Med J       Date:  1978-09-02

Review 7.  Persistent increase in alpha-fetoprotein level in a patient without underlying liver disease who underwent curative resection of hepatocellular carcinoma. A case report and review of the literature.

Authors:  Isidoro Di Carlo; Maurizio Mannino; Adriana Toro; Annalisa Ardiri; Antonio Galia; Giovanni Cappello; Gaetano Bertino
Journal:  World J Surg Oncol       Date:  2012-05-06       Impact factor: 2.754

8.  Expression of AFP and Rev-Erb A/Rev-Erb B and N-CoR in fetal rat liver, liver injury and liver regeneration.

Authors:  Volker Meier; Kyrylo Tron; Danko Batusic; Abderrahim Elmaouhoub; Giuliano Ramadori
Journal:  Comp Hepatol       Date:  2006-07-05

Review 9.  Hepatocellular carcinoma among cirrhotics--utility of screening and surveillance programs--review article.

Authors:  R Opriță; I B Diaconescu; G Lupu; A Lupu; B Cristea; M R Bratu
Journal:  J Med Life       Date:  2014 Oct-Dec

10.  Consensus of Minimally Invasive and Multidisciplinary Comprehensive Treatment for Hepatocellular Carcinoma - 2020 Guangzhou Recommendations.

Authors:  Qi-Feng Chen; Wang Li; Simon Chun-Ho Yu; Yi-Hong Chou; Hyunchul Rhim; Xiaoming Yang; Lujun Shen; Annan Dong; Tao Huang; Jinhua Huang; Fujun Zhang; Weijun Fan; Ming Zhao; Yangkui Gu; Zhimei Huang; Mengxuan Zuo; Bo Zhai; Yueyong Xiao; Ming Kuang; Jiaping Li; Jianjun Han; Wei Song; Jie Ma; Peihong Wu
Journal:  Front Oncol       Date:  2021-07-02       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.